NASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free ACAD Stock Alerts $18.72 +0.24 (+1.30%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$18.16▼$18.7750-Day Range$18.48▼$30.6652-Week Range$17.71▼$33.99Volume2.19 million shsAverage Volume1.90 million shsMarket Capitalization$3.08 billionP/E RatioN/ADividend YieldN/APrice Target$36.35 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ACADIA Pharmaceuticals alerts: Email Address ACADIA Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside94.2% Upside$36.35 Price TargetShort InterestBearish6.56% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.16Based on 28 Articles This WeekInsider TradingSelling Shares$335,105 Sold Last QuarterProj. Earnings Growth80.30%From $0.66 to $1.19 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.77 out of 5 starsMedical Sector258th out of 947 stocksPharmaceutical Preparations Industry118th out of 435 stocks 4.4 Analyst's Opinion Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.35, ACADIA Pharmaceuticals has a forecasted upside of 94.2% from its current price of $18.72.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.56% of the outstanding shares of ACADIA Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently increased by 14.76%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACAD. Previous Next 1.6 News and Social Media Coverage News SentimentACADIA Pharmaceuticals has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for ACADIA Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest21 people have searched for ACAD on MarketBeat in the last 30 days. This is an increase of 24% compared to the previous 30 days.MarketBeat FollowsOnly 12 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $335,105.00 in company stock.Percentage Held by Insiders27.50% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.29% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow by 80.30% in the coming year, from $0.66 to $1.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is -49.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is -49.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 7.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Read More ACAD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACAD Stock News HeadlinesMarch 18, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Edwards Lifesciences (EW) and Aveanna Healthcare Holdings (AVAH)March 16, 2024 | americanbankingnews.comShort Interest in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Expands By 14.8%March 18, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 15, 2024 | businesswire.comAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 14, 2024 | investorplace.com3 Pharma Stocks to Sell in March Before They Crash & BurnMarch 13, 2024 | markets.businessinsider.comGrabar Law Office Investigates Claims on Behalf of Shareholders of Acadia Pharmaceuticals Inc. (ACAD)March 13, 2024 | finance.yahoo.comAcadia Pharmaceuticals to Participate in the UBS Virtual CNS DayMarch 13, 2024 | seekingalpha.comEvaluating Acadia's Market Position Following Pimavanserin's Clinical SetbackMarch 18, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: March 13, 2024 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $32.00 Price Target at Needham & Company LLCMarch 13, 2024 | markets.businessinsider.comACADIA Pharmaceuticals Sinks After Schizophrenia Drug Failed In Late-stage StudyMarch 13, 2024 | msn.comThese Stocks Are Moving the Most Today: Oracle, Acadia Pharmaceuticals, Vail Resorts, and MoreMarch 13, 2024 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Gap Down on Analyst DowngradeMarch 12, 2024 | finance.yahoo.comAcadia drug fails schizophrenia trial, setting back company’s expansion plansMarch 12, 2024 | investopedia.comAcadia Pharmaceuticals Stock Sinks After Schizophrenia Drug Study Falls ShortMarch 12, 2024 | seekingalpha.comAcadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May ContinueMarch 12, 2024 | marketwatch.comAcadia Pharmaceuticals Shares Fall Premarket After Study FailureMarch 12, 2024 | msn.comTrial Setback For Acadia Pharmaceuticals' Late-Stage Schizophrenia Trial: DetailsMarch 12, 2024 | msn.comThese Stocks Are Moving the Most Today: Oracle, Nvidia, Acadia Pharmaceuticals, Archer Daniels, On Holding, Vail Resorts, and MoreMarch 12, 2024 | finance.yahoo.comAcadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia StudyMarch 12, 2024 | investorplace.comWhy Are Airline Stocks Down Today?March 12, 2024 | investorplace.comWhy Are Airline Stocks Down Today?March 12, 2024 | investorplace.comWhy Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today?March 12, 2024 | americanbankingnews.comMizuho Downgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) to NeutralMarch 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACADMarch 11, 2024 | msn.comAcadia's late-stage trial for schizophrenia treatment did not meet main goalMarch 11, 2024 | msn.comAcadia Pharma’s stock falls 15% after failed drug trialSee More Headlines Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/18/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACAD CUSIPN/A CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees597Year FoundedN/APrice Target and Rating Average Stock Price Target$36.94 High Stock Price Target$95.00 Low Stock Price Target$25.00 Potential Upside/Downside+98.9%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($0.38) Trailing P/E RatioN/A Forward P/E Ratio28.57 P/E GrowthN/ANet Income$-61,290,000.00 Net Margins-8.44% Pretax Margin-7.03% Return on Equity-15.67% Return on Assets-9.15% Debt Debt-to-Equity RatioN/A Current Ratio2.42 Quick Ratio2.28 Sales & Book Value Annual Sales$726.44 million Price / Sales4.21 Cash FlowN/A Price / Cash FlowN/A Book Value$2.63 per share Price / Book7.06Miscellaneous Outstanding Shares164,772,000Free Float119,460,000Market Cap$3.06 billion OptionableOptionable Beta0.40 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Stephen R. Davis J.D. (Age 63)President, CEO & Director Comp: $1.46MMr. Mark C. Schneyer (Age 49)Executive VP & CFO Comp: $701.03kMr. Brendan P. Teehan (Age 55)Executive VP, COO & Head of Commercial Comp: $724.31kMr. James K. Kihara (Age 43)VP, Chief Accounting Officer & Corporate Controller Dr. Douglas J. Williamson M.D. (Age 62)Executive VP & Head of Research & Development Dr. Kevin R. Oliver Ph.D. (Age 54)Senior VP & Chief Business Officer Ms. Stephanie KimSenior Vice President of Regulatory AffairsMs. Erika Parker ZavodSenior Vice President of Strategy, Planning, Research & DevelopmentMs. Kimberly J. Manhard (Age 64)Senior Vice President of Global Strategic Planning & Execution More ExecutivesKey CompetitorsIDEAYA BiosciencesNASDAQ:IDYAXenon PharmaceuticalsNASDAQ:XENEBausch Health CompaniesNYSE:BHCAmicus TherapeuticsNASDAQ:FOLDArvinasNASDAQ:ARVNView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 220,731 shares on 3/11/2024Ownership: 8.130%Fisher Asset Management LLCBought 143,054 shares on 3/5/2024Ownership: 0.087%Wellington Management Group LLPBought 38,987 shares on 3/5/2024Ownership: 0.024%Goldman Sachs Group Inc.Bought 46,100 shares on 3/1/2024Ownership: 0.000%Stephen DavisSold 5,577 sharesTotal: $137,584.59 ($24.67/share)View All Insider TransactionsView All Institutional Transactions ACAD Stock Analysis - Frequently Asked Questions Should I buy or sell ACADIA Pharmaceuticals stock right now? 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACAD shares. View ACAD analyst ratings or view top-rated stocks. What is ACADIA Pharmaceuticals' stock price target for 2024? 15 brokers have issued 1 year target prices for ACADIA Pharmaceuticals' shares. Their ACAD share price targets range from $25.00 to $95.00. On average, they anticipate the company's share price to reach $36.35 in the next twelve months. This suggests a possible upside of 94.2% from the stock's current price. View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts. How have ACAD shares performed in 2024? ACADIA Pharmaceuticals' stock was trading at $31.31 at the beginning of 2024. Since then, ACAD shares have decreased by 40.2% and is now trading at $18.72. View the best growth stocks for 2024 here. Are investors shorting ACADIA Pharmaceuticals? ACADIA Pharmaceuticals saw a increase in short interest in February. As of February 29th, there was short interest totaling 10,810,000 shares, an increase of 14.8% from the February 14th total of 9,420,000 shares. Based on an average daily volume of 1,950,000 shares, the days-to-cover ratio is presently 5.5 days. View ACADIA Pharmaceuticals' Short Interest. When is ACADIA Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our ACAD earnings forecast. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by $0.04. The biopharmaceutical company had revenue of $231.04 million for the quarter, compared to analysts' expectations of $223.79 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 15.67% and a negative net margin of 8.44%. ACADIA Pharmaceuticals's revenue for the quarter was up 69.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.26) EPS. What ETFs hold ACADIA Pharmaceuticals' stock? ETFs with the largest weight of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), Invesco Biotechnology & Genome ETF (PBE), First Trust NYSE Arca Biotechnology Index Fund (FBT), Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings? ACADIA Pharmaceuticals updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $930.0 million-$1.0 billion, compared to the consensus revenue estimate of $965.1 million. What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO? 8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL). Who are ACADIA Pharmaceuticals' major shareholders? ACADIA Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.16%), Vanguard Group Inc. (8.13%), RTW Investments LP (6.85%), Price T Rowe Associates Inc. MD (3.15%), Palo Alto Investors LP (1.47%) and First Trust Advisors LP (1.08%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, James Kihara, Laura Brege, Mark C Schneyer, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACAD) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.